Thirty-seven male patients diagnosed with combat-related PTSD based on DSM-IV-TR criteria were randomly assigned to two groups : 18 patients , the case group , received pregabalin ( 300 mg/day ) while 19 patients , the control group , received placebo for 6 weeks .